These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 11780579)

  • 1. Tumour necrosis factor and cancer treatment: a historical review and perspectives.
    Terlikowski SJ
    Rocz Akad Med Bialymst; 2001; 46():5-18. PubMed ID: 11780579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor-selective mutants of tumour necrosis factor in the therapy of cancer: preclinical studies.
    Brouckaert P; Ameloot P; Cauwels A; Everaerdt B; Libert C; Takahashi N; Van Molle W; Fiers W
    Circ Shock; 1994 Aug; 43(4):185-90. PubMed ID: 7895324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tumor necrosis factor: pleiotropic cytokine].
    Chouaib S; Robinet E; Zyad A; Branellec D
    Bull Cancer; 1992; 79(10):935-49. PubMed ID: 1292760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective.
    Wiemann B; Starnes CO
    Pharmacol Ther; 1994; 64(3):529-64. PubMed ID: 7724661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biology of tumor necrosis factor-alpha- implications for psoriasis.
    Schottelius AJ; Moldawer LL; Dinarello CA; Asadullah K; Sterry W; Edwards CK
    Exp Dermatol; 2004 Apr; 13(4):193-222. PubMed ID: 15086336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tumor necrosis factor-alpha--biological and immunologic properties].
    Chciałowski A; Targowski T; Bajera I; Jahnz-Rózyk K
    Pol Merkur Lekarski; 1997 Jun; 2(12):392-5. PubMed ID: 9424334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional application of TNF alpha in the treatment of cancer: a preclinical-clinical interactive program.
    Eggermont AM; Manusama ER; ten Hagen TL
    J Inflamm; 1995-1996; 47(1-2):104-13. PubMed ID: 8913937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor, cancer and anticancer therapy.
    Mocellin S; Rossi CR; Pilati P; Nitti D
    Cytokine Growth Factor Rev; 2005 Feb; 16(1):35-53. PubMed ID: 15733831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour necrosis factor: strategies for improving the therapeutic index.
    Corti A; Marcucci F
    J Drug Target; 1998; 5(6):403-13. PubMed ID: 9783674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective up-regulation of tumor necrosis factor receptor I in tumor-bearing rats with cancer-related cachexia.
    Catalano MG; Fortunati N; Arena K; Costelli P; Aragno M; Danni O; Boccuzzi G
    Int J Oncol; 2003 Aug; 23(2):429-36. PubMed ID: 12851692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects.
    Gerspach J; Pfizenmaier K; Wajant H
    Biofactors; 2009; 35(4):364-72. PubMed ID: 19484741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exogenous and endogenous tumour necrosis factor therapy.
    Soma G; Mizuno D
    Cancer Surv; 1989; 8(4):837-52. PubMed ID: 2701730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon (IFN)-gamma is a main mediator of keratinocyte (HaCaT) apoptosis and contributes to autocrine IFN-gamma and tumour necrosis factor-alpha production.
    Konur A; Schulz U; Eissner G; Andreesen R; Holler E
    Br J Dermatol; 2005 Jun; 152(6):1134-42. PubMed ID: 15948973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines.
    Kim DM; Koo SY; Jeon K; Kim MH; Lee J; Hong CY; Jeong S
    Cancer Res; 2003 Feb; 63(3):621-6. PubMed ID: 12566305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy.
    Younes A; Kadin ME
    J Clin Oncol; 2003 Sep; 21(18):3526-34. PubMed ID: 12972530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2) immunotherapy with ranimustine chemotherapy and concurrent radiation therapy for malignant astrocytomas.
    Fukushima T; Yamamoto M; Oshiro S; Tsugu H; Hirakawa K; Soma G
    Anticancer Res; 2003; 23(6a):4473-81. PubMed ID: 14666736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
    Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
    J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined effect of tumor necrosis factor-alpha and ionizing radiation on the induction of apoptosis in 5637 bladder carcinoma cells.
    Baierlein SA; Distel L; Sieber R; Weiss C; Rödel C; Sauer R; Rödel F
    Strahlenther Onkol; 2006 Aug; 182(8):467-72. PubMed ID: 16896593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response.
    Marotte H; Maslinski W; Miossec P
    Arthritis Res Ther; 2005; 7(1):R149-55. PubMed ID: 15642135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.